China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

In 2023, West Virginia had the highest share of adults (**** percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Diabetes prevalence is projected to increase across all world regions by 2050, with the Middle East and North Africa expected to face the highest rates at 21 percent. This alarming trend highlights the growing global health challenge posed by diabetes, which already affects hundreds of millions of people worldwide and strains healthcare systems. Global impact and economic burden The number of diabetics globally is set to rise from nearly 589 million in 2024 to around 853 million by 2050. This surge in cases is accompanied by a significant economic burden, with global expenditures for diabetes treatment expected to grow from about 1.02 trillion U.S. dollars in 2024 to approximately 1.04 trillion U.S. dollars by 2050. The United States alone is projected to spend around 404.5 billion U.S. dollars on diabetes-related healthcare in 2024, underscoring the massive financial implications of this chronic condition. Regional disparities and future outlook While the Middle East and North Africa region is projected to have the highest diabetes prevalence by 2050, other regions will also see substantial increases. Africa is expected to experience a 142 percent rise in diabetic cases from 2024 to 2050, despite having the lowest prevalence among world regions. China is anticipated to remain the country with the highest number of diabetics, reaching approximately 168 million cases by 2050. Notably, Pakistan is forecast to surpass the United States in terms of diabetic population by mid-century, reflecting shifting global health dynamics and the need for targeted interventions in developing nations.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Diabetes prevalence in Massachusetts has been steadily increasing.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.

The construction of diabetes dataset was explained. The data were collected from the Iraqi society, as they data were acquired from the laboratory of Medical City Hospital and (the Specializes Center for Endocrinology and Diabetes-Al-Kindy Teaching Hospital). Patients' files were taken and data extracted from them and entered in to the database to construct the diabetes dataset. The data consist of medical information, laboratory analysis. The data attribute are: The data consist of medical information, laboratory analysis… etc. The data that have been entered initially into the system are: No. of Patient, Sugar Level Blood, Age, Gender, Creatinine ratio(Cr), Body Mass Index (BMI), Urea, Cholesterol (Chol), Fasting lipid profile, including total, LDL, VLDL, Triglycerides(TG) and HDL Cholesterol , HBA1C, Class (the patient's diabetes disease class may be Diabetic, Non-Diabetic, or Predict-Diabetic).

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 6.900 % in 2021. This records an increase from the previous number of 5.300 % for 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.100 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 6.900 % in 2021 and a record low of 5.300 % in 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

The China diabetes treatment market, valued at approximately $12.34 billion in 2025, exhibits a Compound Annual Growth Rate (CAGR) of 2.70% from 2025 to 2033. This growth is fueled by several key factors. The rising prevalence of diabetes in China, driven by an aging population, increasing urbanization, and lifestyle changes including sedentary habits and poor diets, is a primary driver. Furthermore, increasing awareness of diabetes and improved access to healthcare, particularly in urban areas, are contributing to higher diagnosis rates and treatment adoption. The market is segmented across various drug classes, including insulins (basal/long-acting, bolus/fast-acting, human insulins, and biosimilars), oral anti-diabetic drugs (biguanides, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and dopamine D2 receptor agonists), and non-insulin injectables (GLP-1 receptor agonists and amylin analogues). Competition is fierce amongst major pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, and Merck, each vying for market share with their diverse portfolios of innovative and established therapies. While the market shows positive growth, challenges remain. These include affordability concerns, especially in rural areas, and the need for improved patient education and adherence to treatment regimens. Future market growth will likely depend on the development and adoption of newer, more effective treatments, pricing strategies that cater to the diverse socioeconomic landscape of China, and continued investment in diabetes prevention and management initiatives. The projected market expansion is expected to be driven primarily by the increasing adoption of newer drug classes, such as SGLT-2 inhibitors and GLP-1 receptor agonists, which offer improved efficacy and safety profiles compared to older treatments. The continued introduction of biosimilars will also contribute to market growth by offering more affordable insulin options. However, the growth trajectory will also be influenced by government healthcare policies, including price controls and reimbursement strategies. Further segmentation analysis would reveal the relative market share of each drug class and the dominance of specific brands within those segments. Understanding the regional variations in diabetes prevalence and access to healthcare will be crucial for strategic market positioning and investment decisions. This necessitates an ongoing monitoring of the evolving regulatory landscape and patient needs to accurately predict future market trends and opportunities. Recent developments include: April 2023: National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., October 2022: Hua Medicine announced that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator developed by the Company, was officially approved by the National Medical Products Administration (NMPA) of China. It is to be used as monotherapy for drug naïve Type 2 diabetes patients or combined with metformin in metformin-tolerated Type 2 diabetes to control blood glucose levels.. Notable trends are: The oral anti-diabetic drugs segment holds the highest market share in the China Diabetes Care Drugs Market in the current year.

Number and percentage of persons having been diagnosed with diabetes, by age group and sex.

Diabetes Diet Market Outlook

The global diabetes diet market size was valued at approximately USD 8.5 billion in 2023, projected to grow at a robust CAGR of 5.9% reaching around USD 14.9 billion by 2032. This growth trajectory is primarily fueled by the increasing prevalence of diabetes worldwide, which is urging a shift towards specialized dietary plans to manage the condition effectively. The burgeoning awareness regarding the benefits of a diabetes-specific diet, combined with an increase in health-consciousness among consumers, is driving significant demand in this market. Furthermore, the technological advancements in food processing and the introduction of innovative diabetes-friendly products are anticipated to bolster market expansion over the coming years.

The surge in diabetic populations globally is a major growth factor for the diabetes diet market. In many parts of the world, lifestyle changes and dietary shifts have led to a sharp rise in diabetes cases, particularly Type 2 diabetes. With urbanization, sedentary lifestyles, and the prevalence of unhealthy eating habits contributing to this rise, the need for dietary interventions has become more pronounced. Diabetes-specific diets play a crucial role in managing blood glucose levels, which in turn reduces the risk of complications associated with the disease. As healthcare professionals increasingly recommend tailored diet plans as part of diabetes management, the demand for specialized products continues to rise, fostering market growth.

The growing geriatric population also contributes significantly to the diabetes diet market’s expansion. Older individuals are more susceptible to Type 2 diabetes due to various factors, including reduced physical activity and metabolic changes. This demographic shift is leading to an increased market for diabetes-friendly dietary solutions tailored to meet the nutritional needs of older adults. Moreover, as life expectancy increases, the need for long-term diabetes management solutions, including appropriate diets, becomes more critical, further propelling market demand. The development of age-specific dietary products that cater to the geriatric population's unique requirements is becoming a focal point for manufacturers, thus driving innovation in the market.

Technological advancements and product innovation are also key drivers of market growth. The introduction of low-calorie sweeteners, meal replacements, and low-carbohydrate foods offers diabetic consumers a wider variety of choices that cater to their nutritional needs and preferences. These innovations are driven by a surge in research and development efforts aimed at enhancing the nutritional content and taste of diabetes-friendly products. Additionally, the growing trend of personalized nutrition, which involves tailoring diet plans based on individual health conditions, is encouraging manufacturers to invest in novel food solutions. This trend is expected to continue fueling the diabetes diet market as consumers seek products that align with their health goals and dietary restrictions.

The regional outlook for the diabetes diet market is promising, with North America leading due to its high diabetes prevalence and well-established healthcare infrastructure. In Europe, the market is driven by increasing health-consciousness and governmental initiatives promoting healthy lifestyles. The Asia Pacific region, exhibiting the highest growth rate, is fueled by rising diabetes incidences and growing awareness about diabetes management. Latin America and the Middle East & Africa are also witnessing market expansion due to improved healthcare access and increasing diabetes awareness campaigns. Each region's unique demographic and economic factors are shaping the growth trajectory of the diabetes diet market and creating opportunities for tailored market strategies.

Product Type Analysis

The diabetes diet market, segmented by product type, encompasses meal replacements, low-calorie sweeteners, low-carbohydrate foods, and other tailored food products. Meal replacements are gaining traction as they offer convenient solutions for individuals managing their diabetes. These products are designed to provide balanced nutrition while controlling carbohydrate intake, making them attractive to busy consumers. The market for meal replacements is being driven by the demand for easy-to-prepare options that do not compromise on nutritional value. Manufacturers are increasingly focusing on enhancing the taste and texture of these products to appeal to a wider audience, further driving their popularity.

Low-calorie

Dataset from Ministry of Health. For more information, visit https://data.gov.sg/datasets/d_efea9966c502767122171c61d88062db/view

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 data point).

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

This table contains 14784 series, with data for years 1994 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (not all combinations are available): Geography (11 items: Canada; Newfoundland and Labrador; Prince Edward Island; Nova Scotia ...), Age group (14 items: Total; 12 years and over; 15-19 years; 12-19 years; 12-14 years ...), Sex (3 items: Both sexes; Males; Females ...), Diabetes (4 items: Total population for the variable diabetes ;With diabetes; Without diabetes; Diabetes; not stated ...), Characteristics (8 items: Number of persons; Low 95% confidence interval - number of persons; High 95% confidence interval - number of persons; Coefficient of variation for number of persons ...).